UNCLASSIFIED

U.S. Department of Homeland Security
U.S. Customs and Border Protection

INTELLIGENCE ALERT

CBP-OI-IA-014U-17

11 July 2017

(U) Fentanyl Analogues Not Resistant to Narcan® (Naloxone)

- (U) Contrary to recent news reporting, there are no fentanyl analogues resistant to Naloxone. News reports indicated a "new" fentanyl analogue, acrylfentanyl, was "extremely powerful" and implied it resisted Naloxone's effects. However, acrylfentanyl binds to the same receptors within the human body as fentanyl, meaning correctly administered Naloxone is effective against it.
 - (U) Naloxone belongs to a category of drugs known as opioid antagonists. Opioid antagonists reverse opioids' effects by binding to the same opioid receptors in the human body as opioids. If administered quickly and at a sufficient dose, Naloxone and other opioid antagonists are effective against all opioids—including fentanyl and its analogues—regardless of their potency, according to the National Heroin Coordination Group.³
 - (U) Acrylfentanyl is comparable in potency to other illicit fentanyl analogues. Depending on dosage, acrylfentanyl may be more potent than fentanyl and can maintain its analgesic effects longer, according to the European Monitoring Centre for Drugs and Drug Addiction.^{4,5}
 - (U) Acrylfentanyl's decades-long existence proves that it is not a new analogue, according to the European Monitoring Centre for Drugs and Drug Addiction.⁶

(U) Implications

- (U) The misbelief in a Naloxone-resistant fentanyl, particularly acrylfentanyl, will persist until media outlets, journalists, and the public learn more about the opioid-Naloxone relationship. An abundance of accurate and legitimate information is available to the public on both fentanyl and acrylfentanyl. The Substance Abuse and Mental Health Services Administration and the Bureau of Justice Assistance provide excellent overviews of opioids and Naloxone, respectively.^{7,8}
- **(U) Reporting Notice:** This product was prepared by U.S. Customs and Border Protection, Office of Intelligence and coordinated with the Office of National Drug Control Policy. Comments and queries may be directed to the Analytic Standards and Programs Division, Production Management Branch at:

(U) **Warning:** The information contained herein remains under the control of the Department of Homeland Security (DHS), through U.S. Customs and Border Protection (CBP). It is being disseminated for authorized law enforcement purposes only.

UNCLASSIFIED

CBP Office of Intelligence

CBPOIProductionManagement@cbp.dhs.gov CBP_OI_Production_Management@dhs.sgov.gov CBPOIProductionManagement@dhs.ic.gov

- (U) **FEEDBACK**: For general comments or questions related to the dissemination of this document, please e-mail the CBP OI Production Management inbox at CBPOIProductionManagement@cbp.dhs.gov or call 202-325-3659.
- (U) Please participate in a brief customer feedback survey regarding this product. Your feedback is important to our efforts to improve the quality and impact of our products on your mission. Please scroll to the last page to find the form and then follow a few simple steps to complete and submit your response. Thank you.

¹ (U) | National Heroin Coordination Group | 30 May 2017 | (U) Acrylfentanyl and Naloxone Effectiveness | Extracted information classification is U | Overall document classification is U | (U) Source is an official communication from a U.S. Law Enforcement body | http://www.newsweek.com/fentanyl-georgia-naloxone-resistant-synthetic-opioids-acrylfentanyl-629846
² (U) | Newsweek | 28 June 2017 | (U) Fentanyl Found In Georgia Resists Life-Saving Naloxone Antidote | Extracted information classification is U | Overall document classification is U

³ (U) | National Heroin Coordination Group | 30 May 2017 | (U) Acrylfentanyl and Naloxone Effectiveness | Extracted information classification is U | Overall document classification is U | (U) Source is an official communication from a U.S. Law Enforcement body

⁴ (U) | National Heroin Coordination Group | 30 May 2017 | (U) Acrylfentanyl and Naloxone Effectiveness | Extracted information classification is U | Overall document classification is U | (U) Source is an official communication from a U.S. Law Enforcement body

⁵ (U) | European Monitoring Centre for Drugs and Drug Addiction | 17 November 2016 | (U) Acryloylfentanyl: EMCDDA-Europol Joint Report on a new psychoactive substance: N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) | Extracted information classification is U | Overall document classification is U |

http://www.emcdda.europa.eu/system/files/publications/3873/TI_PUBPDF_TDAS17001ENN_PDFWEB_20170221105322.pdf

(U) | European Monitoring Centre for Drugs and Drug Addiction | 17 November 2016 | (U) Acryloylfentanyl: EMCDDA-Europol Joint Report on a new psychoactive substance: N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) | Extracted information classification is U | Overall document classification is U |

http://www.emcdda.europa.eu/system/files/publications/3873/TI_PUBPDF_TDAS17001ENN_PDFWEB_20170221105322.pdf ⁷ (U) | Substance Abuse and Mental Health Administration | 20 January 2016 | (U) SAMHSA Opioid Overdose Prevention Toolkit | Extracted information is classification U | Overall document classification is U | https://store.samhsa.gov/product/SAMHSA-Opioid-Overdose-Prevention-Toolkit/SMA16-4742

⁸ (U) | Bureau of Justice Assistance | 2016 | (U) Law Enforcement Naloxone Toolkit | Extracted information classification is U | Overall document classification is U | https://www.bjatraining.org/tools/naloxone/Naloxone-Background

UNCLASSIFIED

U.S. Department of Homeland Security
U.S. Customs and Border Protection

CUSTOMER SURVEY

lease rate your level of satisfaction			Type of Customer		
1. Product Number and Title:					
2. Date you received this produc	t:				
3. How did you obtain this produc	ct:				
4. Please rate your satisfaction v	vith each of the 1	following:			
	Very Satisfied	Somewhat Satisfied	Somewhat Dissatisfied	Very Dissatisfied	N/A
Relevancy to CBP mission					
Accuracy of the information provided					

6. For CBP-OI use

To help us understand more about your organization so we can better tailor future products, please provide:

Your Name:
Your Organization:
Your Contact Number:
Your Contact Number:
Your Organization so we can better tailor future products, please provide:
Your Position:
Your Email:

